Sodium Bicarbonate
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Sodium Bicarbonate
Sodium Bicarbonate: Known uses and market status in Australia
Summary
The TxGNN model has no candidate with a score of 0.99 or higher for Sodium Bicarbonate, so there is currently no new predicted indication. The drug’s recorded uses are listed below.
Quick overview
| Item | Content |
|---|---|
| New predicted indications | None (no model candidate scored 0.99 or higher) |
| Known uses recorded for this drug | 5 |
| Evidence level | Not applicable |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
Known uses recorded for this drug
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| duodenal ulcer | Licence in another country |
| gastritis | Licence in another country |
| hyperacidity | Licence in another country |
| nausea | Licence in another country |
| vomiting | Licence in another country |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| none | none |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| none |
Australia Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 452T | nan | nan | Valid |
Safety Considerations
Drug Interactions (100 interactions were identified in total; the main ones are listed below):
- Moderate: doxycycline, tetracycline, minocycline, acetylsalicylic acid, atropine, bisacodyl, chlorpropamide, acetohexamide, glipizide, ephedrine, pancrelipase
- Minor: famotidine, ranitidine, cimetidine, hydrocortisone, triamcinolone, dexamethasone, betamethasone, misoprostol
Please refer to the TGA-approved Product Information (PI) for warnings and contraindications.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.